La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Zai Lab Gestion
Gestion contrôle des critères 2/4
Zai Lab's CEO is Samantha Du, appointed in Jan 2014, has a tenure of 10.58 years. total yearly compensation is $12.04M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 0.85% of the company’s shares, worth $14.33M. The average tenure of the management team and the board of directors is 1.9 years and 5.8 years respectively.
Informations clés
Samantha Du
Directeur général
US$12.0m
Rémunération totale
| Pourcentage du salaire du PDG | 7.2% |
| Durée du mandat du directeur général | 10.6yrs |
| Propriété du PDG | 0.9% |
| Durée moyenne d'occupation des postes de direction | 1.9yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.8yrs |
Mises à jour récentes de la gestion
Recent updates
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Jun 12
Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
May 14A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M
Aug 09China accepts Zai Lab's biologics license application for neuromuscular disorder drug
Jul 13Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$298m |
| Mar 31 2024 | n/a | n/a | -US$339m |
| Dec 31 2023 | US$12m | US$869k | -US$335m |
| Sep 30 2023 | n/a | n/a | -US$301m |
| Jun 30 2023 | n/a | n/a | -US$393m |
| Mar 31 2023 | n/a | n/a | -US$410m |
| Dec 31 2022 | US$20m | US$830k | -US$443m |
| Sep 30 2022 | n/a | n/a | -US$593m |
| Jun 30 2022 | n/a | n/a | -US$529m |
| Mar 31 2022 | n/a | n/a | -US$554m |
| Dec 31 2021 | US$15m | US$774k | -US$704m |
| Sep 30 2021 | n/a | n/a | -US$569m |
| Jun 30 2021 | n/a | n/a | -US$537m |
| Mar 31 2021 | n/a | n/a | -US$454m |
| Dec 31 2020 | US$9m | US$689k | -US$269m |
| Sep 30 2020 | n/a | n/a | -US$239m |
| Jun 30 2020 | n/a | n/a | -US$240m |
| Mar 31 2020 | n/a | n/a | -US$201m |
| Dec 31 2019 | US$9m | US$656k | -US$195m |
| Sep 30 2019 | n/a | n/a | -US$212m |
| Jun 30 2019 | n/a | n/a | -US$181m |
| Mar 31 2019 | n/a | n/a | -US$160m |
| Dec 31 2018 | US$6m | US$638k | -US$139m |
Rémunération vs marché: Samantha's total compensation ($USD12.04M) is above average for companies of similar size in the US market ($USD5.62M).
Rémunération et revenus: Samantha's compensation has been consistent with company performance over the past year.
PDG
Samantha Du (58 yo)
10.6yrs
Titularisation
US$12,042,285
Compensation
Dr. Ying Du, Ph D., also known as Samantha, serves as Founding Managing Director at Quan Capital. She served as Venture Partner at Sequoia Capital China.Dr. Du serves as an adjunct professor at Fudan Univ...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 10.6yrs | US$12.04m | 0.85% $ 14.3m | |
| President & COO | 2yrs | US$5.55m | 0.032% $ 541.1k | |
| President and Head of Global Research & Development | 1.6yrs | US$4.87m | 0.021% $ 348.7k | |
| Chief Financial Officer | 1.1yrs | US$2.01m | 0.015% $ 248.4k | |
| Chief Scientific Officer | 1.8yrs | pas de données | pas de données | |
| Senior VP & Head of Investor Relations | 1.3yrs | pas de données | pas de données | |
| Chief Legal Officer & Joint Corporate Secretary | 4yrs | US$5.63m | 0.026% $ 443.2k | |
| Executive VP & Head of Clinical Operations | 10.6yrs | pas de données | pas de données | |
| Chief Business Officer | 10.6yrs | pas de données | pas de données | |
| Chief Operating Officer of R&D | 9.6yrs | pas de données | pas de données | |
| Chief Commercial Officer of Greater China | less than a year | pas de données | pas de données | |
| Chief Medical Officer of Oncology | less than a year | pas de données | pas de données |
1.9yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Gestion expérimentée: ZLAB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 10.6yrs | US$12.04m | 0.85% $ 14.3m | |
| Independent Director | 4.6yrs | US$574.35k | 0.041% $ 692.1k | |
| Independent Director | 7.6yrs | US$576.15k | 0.37% $ 6.2m | |
| Lead Independent Director | 7.6yrs | US$608.44k | 0.069% $ 1.2m | |
| Member of Scientific Advisory Board | 8.6yrs | pas de données | pas de données | |
| Independent Director | 2.8yrs | US$570.77k | 0.053% $ 896.6k | |
| Independent Director | 5.8yrs | US$567.03k | 0.054% $ 906.8k | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | 5.5yrs | pas de données | pas de données | |
| Independent Director | 2.8yrs | US$564.98k | 0.028% $ 475.0k | |
| Independent Director | 6yrs | US$557.48k | 0.048% $ 807.4k | |
| Member of Scientific Advisory Board | 4.7yrs | pas de données | pas de données |
5.8yrs
Durée moyenne de l'emploi
67.5yo
Âge moyen
Conseil d'administration expérimenté: ZLAB's board of directors are considered experienced (5.8 years average tenure).